PMID- 22497582
OWN - NLM
STAT- MEDLINE
DCOM- 20121031
LR  - 20151119
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 132
IP  - 6
DP  - 2012 Jun
TI  - Potential prognostic and therapeutic role for angiogenesis markers in laryngeal 
      carcinoma.
PG  - 574-82
LID - 10.3109/00016489.2011.652308 [doi]
AB  - Angiogenesis is a hallmark of cancer, fundamental to its growth. The 'angiogenic 
      switch' occurs when pro-angiogenic factors are not balanced by anti-angiogenic 
      factors. A correlation between angiogenic properties and oncological prognosis 
      (for laryngeal squamous cell carcinoma (LSCC) too) was first hypothesized in the 
      1990s. An exhaustive literature review was performed to investigate available 
      data on angiogenesis markers and their biological role and therapeutic potential 
      in LSCC. The prognostic significance of microvascular density in LSCC was 
      investigated with endothelial targets, e.g. CD105, CD34, and CD31. Epidermal 
      growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF 
      receptor 2, angiogenin, hypoxia-inducible factor 1, and other biological markers 
      were also studied. Only anti-EGFR therapy has been approved by the USFood and 
      Drug Administration (FDA) for head and neck carcinoma in recent years, while 
      several agents interfering with VEGF and its receptors are being studied. 
      Experimental findings indicate that anti-CD105 monoclonal antibodies efficiently 
      inhibit tumor angiogenesis. There are two main ways to approach the vascular 
      profile of solid malignancies: by inhibiting new vessel formation 
      (anti-angiogenic therapy) or selectively damaging neoplastic vessels (vascular 
      targeting therapy). In advanced LSCC, both these strategies seem promising and 
      warrant further preclinical and clinical investigation.
FAU - Lionello, Marco
AU  - Lionello M
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Staffieri, Alberto
AU  - Staffieri A
FAU - Marioni, Gino
AU  - Marioni G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120412
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - *Carcinoma, Squamous Cell/blood supply/drug therapy/metabolism
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Humans
MH  - *Laryngeal Neoplasms/blood supply/metabolism/therapy
MH  - Neovascularization, Pathologic/*metabolism/pathology
MH  - Prognosis
MH  - Treatment Outcome
EDAT- 2012/04/14 06:00
MHDA- 2012/11/01 06:00
CRDT- 2012/04/14 06:00
PHST- 2012/04/14 06:00 [entrez]
PHST- 2012/04/14 06:00 [pubmed]
PHST- 2012/11/01 06:00 [medline]
AID - 10.3109/00016489.2011.652308 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2012 Jun;132(6):574-82. doi: 10.3109/00016489.2011.652308. Epub 
      2012 Apr 12.